Stem Cell Initiative Event Summary
Upcoming SlideShare
Loading in...5
×
 

Stem Cell Initiative Event Summary

on

  • 1,423 views

 

Statistics

Views

Total Views
1,423
Views on SlideShare
1,423
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Stem Cell Initiative Event Summary Stem Cell Initiative Event Summary Document Transcript

  • NCL Stem Cell Initiative November 12, 2001 Society for Neuroscience Convention San Diego, California
  • NCL Stem Cell Initiative Summary November 2001 Participants NCLRA Members: Liz Aurelio, Andrew Henery, Phil Milto, Ricky Bennett (not able to attend), Russelle Rankin (not able to attend), Caroline Wright (not able to attend) Attendees: Johan Holmberg - Karolinska Institute, Stockholm, Sweden Mark Kirk - University of Missouri Elizabeth Kriscenski - University of Rochester Karen Mellodew - Kings College Dinos Meletis - Karolinska Institute, Stockholm, Sweden Jason Meyer – University of Missouri David Pearce - University of Rochester Evan Snyder - Harvard Greg Stewart - Genzyme Charles Stiles - Dana - Farber Cancer Institute Harvard Clive Svendsen - University of Madison-Wisconsin Stan Tamaki - StemCells Inc. Nabuko Uchida - StemCells Inc. Dafe Uwanogho - Kings College Su-Chun Zhang - University of Madison-Wisconsin NIH: Giovanna Spinella – NCL Project Coordinator (not able to attend) Interested invitees not able to attend: David Archer – Emory University Fred Gage - The Salk Institute, La Jolla, CA, USA Stephen Goldman – Cornell University Harley Kornblum - UCLA Georg Kuhn, University of Regensburg, Regensburg, Germany Jeffrey Macklis – Harvard Medical School Freda Miller – Montreal Neurological Institute William Mobley - Stanford University Mahendra Rao - Section Chief - StemCell, LNS, GRC National Institute of Aging Rosalind Segal - Dana-Farber Cancer Institute, Harvard Yi Sun – UCLA Henriette van Praag - The Salk Institute, La Jolla, CA, USA Irving Weissman – Stanford University 2 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 About This Document The information that is contained in this document is to be used for reference only and should not be construed as absolute information. The information has been compiled from various sources and represents opinions of those who attended. All information should be used in a constructive nature. The aim of this document is to summarize the discussions of the information presented during the “NCL Stem Cell Initiative” event. Discrepancies and inaccuracies may exist and it is advised to contact conference attendees to obtain detailed information regarding the subject matter. A conference contact list is attached to assist in gaining additional clarity on specific information. Event Objectives The objectives of the event were: • To introduce the NCLRA and NCLs to scientists key in their field of stem cell research. • To present to leaders in stem cell research a high level NCL overview in hope to gain interest in these diseases of children and foster some direction and collaborations for the future • To generate interest in cell mediated approaches to treat NCL disorders through open collaboration with researchers in the field. • To stimulate thought of potential cell mediated strategies to develop treatment for the NCLs The NCLRA The Neuronal Ceroid Lipofuscinoses Research Alliance (NCLRA) is a united group of foundations whose purpose is to aid in the coordination of bringing potential therapies to clinical trials for the three major forms of NCL (INCL, LINCL, JNCL). Through this united effort the alliance can provide the following: • Established network of relevant research information and collaborations with NCL scientists for knowledge transfer • Facilitate the obtainment of necessary NCL tools (data, model access, cDNA, enzymatic assays, cell lines, antibodies, and other reagents…) • Advocate voice to regulatory bodies and agencies • Patient population representation • Strong relationships politically and with governmental agencies (NIH and FDA) • Well funded foundations ready to support therapy development projects 3 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 • Clinical program experience: pre-clinical study design, protocol development, tox. study design, regulatory requirements, detailed feasibility study, work plans… NCLRA Achievements The NCLRA is a proven result driven alliance with many achievements and accomplishments: • Identified, developed, initiated and is funding a multi-million-dollar gene transfer therapy program with the Weill Medical College of Cornell University. • The NCLRA has developed a network of relevant research information and has fostered collaboration between academic groups and private sector biotech companies. • Developed and implemented a not-for-profit therapy development model designed to leverage platform technologies to advance the therapy development process for rare diseases. • The NCLRA has initiated and is sponsoring a small molecule drug-screening program. • Developed a multi-faceted approach to propel therapy development utilizing science, business, awareness, fundraising, politics, and the regulatory bodies of the NIH and FDA to advance therapy development. • Developed business plan to illustrate the large impact of therapy development for NCL target disorders by leveraging learned technologies to other related disorders. • Organized and have held multiple NCL therapy focused workshops with research professionals, private industry biotech organizations, regulatory agencies of the FDA and NIH, clinicians and neurosurgeons driving therapy development for the NCLs. • NCLRA members are nationally recognized by the NIH as NCL authorities. • NCLRA members are regularly invited to NIH sponsored workshops for rare disease therapy development. • Achieved national notoriety of efforts from being featured on CBS national news program 48 Hours. As you can see from the above, the NCLRA has not only pioneered new methodologies in creating unity amongst the scientific community and private foundations, but have taken the basic research and made it reality. 4 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 NCL Scientific Overview The main goal of this event was to introduce the NCLs and the NCLRA to leaders in stem cell research. The purpose of this introduction was to generate interest from these leading scientists, foster collaborations, and identify cell-mediated approaches for future clinical applications. Dr. David Pearce, University of Rochester, presented a scientific NCL overview. The overview highlighted the following facts about the NCLs: • The NCLs are Lysosomal Storage Disorders with known genetic defects. • LSDs have a relatively high prevalence as a group. • NCLs are attractive targets for therapy: o Known defects o Lack of impact of environmental and outside genetic factors on phenotype o Potential cross correction o Regulation not essential o Much is known about the defective proteins o Biochemical markers/intermediate endpoints • NCLs are autosomal recessive, neurodegenerative disorders and are characterized by accumulation of fluorescent pigment in the lysosome. • NCL incidence of 1:12,500 – High incidence level. • Infantile (CLN1), Late Infantile (CLN2), and Juvenile (CLN3) represent the majority of these disease cases. o Infantile (CLN1) – first signs manifest at 6 months. Progresses rapidly. Failure to thrive.  Microencephaly, myoclonic jerks, delayed psychomotor development, seizures. o Late Infantile (CLN2) – first signs manifest at 2-4 years. Progresses rapidly.  Vision loss, ataxia, seizures, and mental deterioration. o Juvenile (CLN3) – first signs manifest at 5-7 years.  Vision loss, ataxia, seizures, and mental deterioration. • CLN1 and CLN2 are enzyme deficient disorders (PPT and TPP enzymes, respectively) with low therapeutic threshold of 10% CNS enzymatic expression. • Reagents available for the NCLs o CLN1 and CLN3 have available mouse models o Cell lines, antibodies, cDNAs, enzymatic assays, histochemical stains… • NCL scientists available and willing to collaborate on therapeutic approaches. Everyone in attendance became well informed about the NCLs and each participant asked meaningful and insightful questions. The overall impression from the attending scientists was the tremendous promise for cell-mediated therapies to treat NCL disorders. The event illustrated the validity of cell-mediated therapies for NCL. 5 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 NCL and Stem Cell Advantages • Good model disorder to pilot therapy technologies. • Risk/benefit ratio is in favor of therapy. • Orphan disease status. • Currently, no other approved therapies. • Well-funded foundation to readily support therapy development projects. • A subset of the NCLs (INCL/LINCL) are perfect targets for cell mediated therapies because it can benefit from both introduction of cells to produce enzyme and for CNS regeneration. Notable Event Accomplishments: • Introduced the NCLs and the NCLRA to leading stem cell research organizations. • Generated interest among stem cell researchers to evaluate cell mediated approaches to treat the NCLs. • Established relationships between different stem cell researchers and the NCLRA. • Confirmed cell mediated therapies have tremendous potential for therapeutic benefit for the NCLs and the NCLs are a good disease target for such treatments. • Identified stem cell research groups with interest in working on the NCLs in the near future and received proposals to investigate cell-mediated strategies for the NCLs. Next steps The NCLRA is contacting interested stem cell research groups to gain insight into a few basic questions regarding cell-mediated therapies for neurodegenerative disorders. The NCLRA is interested in identifying approaches to move stem cell research toward clinical applications. The answers to these questions will aid in evaluating the most promising NCL strategies. The NCLRA’s objective is to identify and develop these strategies into projects that lead to the clinic. Establishing, defining, developing, and funding these projects will be the focus of the NCLRA’s efforts toward stem cell therapies. 1. Is there potential immunogenicity of the stem cells and maybe the elicitation of an antibody response that may or may not eliminate the implanted stem cells and perhaps even cause harm to the brain? How would you recommend handling any immune response issues? 6 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 2. What would be the source of any proposed cells that you would use and why (ES, Spinal Fluid, bone marrow, umbilical cord, olfactory bulb, blood, post mortem neuronal...)? 3. Whether a normalizing (correcting) factor (enzyme or other type of protein) will be secreted from the implanted stem cells and be picked up by non-corrected cells and induce normal function them. What would be your objective of the stem cells (regeneration of neurons or produce missing enzyme or both)? 4. What are the potential scientific and practical barriers that need to be overcome for success? Success being defined as taking basic science to clinic. 5. What would be the "best" theoretical approach to develop cell mediated therapies for the NCLs? How would you propose to proceed in mounting a clinical program? For example: To treat CLN2 you would take adult neuronal stem cells and inject into the parenchyma in 4 different locations while immunosuppressing with immunosuppressant drugs. The stem cells should differentiate into neurons and produce the missing enzyme while regenerating neuronal cells. Pre clinical data to support IND would require several rounds of adult neuronal stem cells injected into CLN1, CLN2 (when available) and normal mice. Track enzyme distribution, cell growth, and characterize function gain to support the IND. 6. What will it take for you to become an interested partner in the NCL's as a therapeutic investigator? And how would you proceed or what steps would you take to develop a clinical program? The NCLRA is interested in funding research that positions the NCLs to move toward the clinic in the future. It is understood that more basic research needs to be performed and a few factors need to be evaluated before a clinical program is mounted. The NCLRA would like to start developing the science that will enable cell-mediated therapies for the NCLs to move toward the clinic (fund projects that lead to the clinic). The alliance is interested in any proposal that researchers might have to develop or support a clinical program. 7 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 Contact Information Attendees Johan Holmberg Mark Kirk Karolinska Institute, Biological Sciences Dept. of Cellular and Molecular Biology University of Missouri Voneulers vag 3, SE171 77 Columbia, Missouri 65211 Stockholm, Sweden kirkm@missouri.edu 46 8 728 6400 (573) 882-6507 johan.holmberg@cmb.ki.se Elizabeth Kriscenski Karen Mellodew University of Rochester Medical Center Kings College Dept. of Biochemistry & Biophysics Institute of Psychiatry 601 Elmwood Avenue, Box 712 Strand, London Rochester, N.Y. 14642 WCZR 2L5 elizabeth_kriscenski@urmc.rochester.edu England, United Kingdom k.mellodew@iop.kcl.ac.uk 44(0) 2078305454 Dinos Meletis Jason Meyer Karolinska Institute, Biological Sciences Dept. of Cellular and Molecular Biology University of Missouri Voneulers vag 3, SE171 77 Columbia, Missouri 65211 Stockholm, Swede jsma43@mizzou.edu dinos.meletis@cmb.ki.se 46 8 728 6400 David Pearce Dr. Greg Stewart University of Rochester Medical Center One Mountain Road Dept. of Biochemistry & Biophysics Framingham MA 01701 601 Elmwood Avenue, Box 712 (800) 326-7002 Rochester, N.Y. 14642 gstewart@genzyme.com (716) 275-3329 David_Pearce@urmc.rochester.edu 8 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 Evan Snyder Charles Stiles 300 Longwood Avenue Dana Farber Cancer Institute Neurology & Pediatrics Division of Cellular and Molecular Biology CH- Enders 248 Smith Research Bldg. Rm. 1070 Boston, MA 02115 44 Binney St. (617) 355-6277/6070/6027 Boston, Mass. 02115 snyder@a1.tch.harvard.edu Charles_Stiles@dfci.harvard.edu (617) 632-3512 Clive Svendsen Stan Tamaki University of Madison-Wisconsin StemCells Inc. 1500 Hiland Ave. 3155 Porter Drive Madison Wisc. 53705 Palo Alto, CA 94304 svendsen@waisman.wisc.edu (650) 475.3100 Tel (608) 263-4900 Stan.Tamaki@stemcellsinc.com Fax (608) 262-2377 Nabuko Uchida Dafe Uwanogho StemCells Inc. Kings College 3155 Porter Drive Institute of Psychiatry Palo Alto, CA 94304 Strand, London (650) 475.3100 WCZR 2L5 nobuko.uchida@stemcellsinc.com England, United Kingdom d.uwanogho@iop.kcl.ac.uk 44(0) 2077080017 Su-Chun Zhang University of Madison-Wisconsin 1500 Hiland Ave. Madison Wisc. 53705 zhang@waisman.wisc.edu Tel (608) 263-4900 Fax (608) 262-2377 9 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 NIH Project Coordinator Dr. Giovanna Spinella National Institute of Health Program Director, Division of Fundamental Neuroscience & Developmental Disorders 7550 Wisconsin Ave Rm 8C-04 Bethesda MD 20892 (301) 496-5821 GS41B@nih.gov Interested invitees not able to attend David Archer Fred H. Gage Children’s Healthcare of Atlanta Laboratory of Genetics 2040 Ridgewood Drive, Room 100 The Salk Institute Atlanta, Georgia 30322 10010 North Torrey Pines Road darcher@emory.edu La Jolla, CA 92037 (404) 727-1378 Tel. 858 453 4100 X 1012 Fax. 858 597 0824 gage@salk.edu Steve Goldman MD, PhD Harley Kornblum Nathan Cummings Professor of Neurology Dept. of Molecular and Medical and Neuroscience Pharmacology Dept. of Neurology/Room E-607 UCLA School of Medicine Cornell Univ Medical Center 1246 CIBI/JLNRC 1300 York Ave 10833 Le Conte Ave. New York, NY 10021 USA Los Angeles Ca. 80024 212-746-6572 (TEL) harley@ucla.edu 212-746-8972 (fax) office (310) 794-7866 sgoldm@mail.med.cornell.edu lab (310) 794-6600 Georg Kuhn Jeffrey D. Macklis, M.D., D.HST. University of Regensburg, Regensburg Associate Professor of Neurology Klinik Und Poliklinik Fuer Neurologie [Neuroscience] Universitaet sstr 84 Harvard Medical School Im Bezirksklinikum Program in Neuroscience, Harvard Medical 93053 Regensburg, Germany School georg.kuhn@klinik.uni-regensburg.de Division of Neuroscience, Children's 0941-944-8997 Hospital 0941-941-3001 320 Longwood Avenue, Enders 354 Boston, MA 02115 E-mail: jeffrey.macklis@tch.harvard.edu TEL: (617) 355-7185 10 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 FAX: (617) 734-1646 Dr. William Mobley Freda Miller Stanford University School of Medicine Montreal Neurological institute SUMC H3160 Centre for neuronal survival Stanford, CA. 94305-5235 3801 university avenue (650) 723-6424 Montreal, QC,H3A 2B4 Canada ngfv1@leland.stanford.edu mdfm@musica.mcgill.ca Mahendra Rao- Section Chief Rosalind Segal StemCell, LNS, GRC Dana Farber Cancer Institute National Institute of Aging Division of Cellular and Molecular Biology 5600 Nathan Shock Drive Smith Research Bldg. Rm. 1070 Baltimore, MD 21224 44 Binney St. raomah@grc.nia.nih.gov Boston, Mass. 02115 TEL (410) 558-8204 (617) 632-4090 Fax (410) 558-8323 Yi Sun Henriette van Praag Dept. of Molecular and Medical Salk Institute for Biological Studies Pharmacology Laboratory of Genetics UCLA School of Medicine 10010 North Torrey Pines Road 1246 CIBI/JLNRC La Jolla, CA 92037 10833 Le Conte Ave. vanpraag@salk.edu Los Angeles Ca. 80024 TEL (858) 453-4100 (310) 794-6600 Fax (858) 453-3015 Irving Weissman Department of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA mv.jfm@forsythe.stanford.edu 11 of 12 NCLRA
  • NCL Stem Cell Initiative Summary November 2001 NCLRA Representatives Liz Aurelio Ricky Bennett 721 Mt Vernon Dr 2 Plymouth Ct San Jose, CA 95125 Flemington, NJ 08822 Phone: 408-448-2530 Phone: 908-782-4140 Ext 239 Fax: 408-264-1767 Email: nclsra@aol.com Email: dlaurelio@earthlink.net Andrew Henery Phil Milto 57 Pleasance Road 459 S State Road 135 St Pauls Cray Greenwood, IN 46142 Orpington, Kent BR5 3AR Phone: 317-888-7396 Phone/Fax: 01689 827913 Fax: 317-888-0504 Email: ahenery@aol.com Email: pmilto@indy.net Russelle Rankin Caroline Wright 27281 Owens Road 13 Bershire Avenue Mendelein, IL 60060 Merewether NSW 2291 Phone: 847-566-5532 Australia Fax: 847-566-6135 Phone/Fax: 612 49636466 Email: russjncl@aol.com Email: caroline@idl.net.au 12 of 12 NCLRA